A hybrid design for dose‐finding oncology clinical trials
Author:
Affiliation:
1. Incyte Corporation Wilmington Delaware USA
2. Merck & Co., Inc. North Wales Pennsylvania USA
3. Genentech South San Francisco California USA
4. Incyte Biosciences International Sàrl Morges Switzerland
Funder
Incyte
Publisher
Wiley
Subject
General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34203
Reference18 articles.
1. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics
2. Design and Analysis of Phase I Clinical Trials
3. Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity
4. Translation of Innovative Designs Into Phase I Trials
5. Range and trend of expected toxicity level (ETL) in standard A+B designs: A report from the children's oncology group
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Three steps toward dose optimization for oncology dose finding;Contemporary Clinical Trials Communications;2024-08
2. Protein tyrosine phosphatases: emerging role in cancer therapy resistance;Cancer Communications;2024-05-13
3. Harnessing the Potential of Natural Products in Cancer Treatment: A Comprehensive Review;J BIOL REG HOMEOS AG;2024
4. HybridDesign: Hybrid Design for Phase I Dose-Finding Studies;CRAN: Contributed Packages;2022-12-15
5. 723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies;Regular and Young Investigator Award Abstracts;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3